



Corporate Sustainability Report

PTC's commitment to corporate responsibility focuses on five key areas: our patients, our people, our community, our values, and our environment.



Table of Contents

Who We Are

PTC Expectations
Culture Statement
Awards & Recognition

Our Environment

Green Operations
Sustainability Efforts

Our Patients

Our Therapeutic Areas
Patient Advocacy
Research & Development/Innovation
Building the Future of Manufacturing
Products & Pipeline
Clinical Trials
PTC Programs to Support Patient
Communities and Access to Care

Our People

Talent Planning
Global Onboarding
Benefits & Wellbeing
Learning & Development
Moment Makers
Workplace and Employee Safety

Our Culture & Community

Our Commitment
Global Equality, Diversity & Inclusion
Global Employee Outreach
Talent Pipeline Program
PTC Political Action Committee

Ethics & Compliance

Compliance Program
Code of Business Conduct & Ethics
Board of Directors
Privacy & Cybersecurity



Caring about environmental, social, and governance issues has been part of PTC's fabric since its founding in 1998. We always strive to improve these efforts that we believe are vitally important to our continued success.

Stuart W. Peltz, Ph.D.
Chief Executive Officer

Who We Are





As a growing, global company with a footprint in more than 50 countries, our mission remains focused on bringing more moments to our patients living with rare diseases and their loved ones. Our approach to corporate social responsibility is rooted in our commitment to patient advocacy, access to medicines, and advancing science.

PTC Culture Statement

Our culture is to make every day count; to care for each other, our community, and for needs of our patients; to be critical, not cynical, of what we do, but not of each other; we strive every day to be better than we were the day before; we want to be part of an important cause and strive to achieve great accomplishments: we are more fearful of not daring to do great things than of failing.


Awards & Recognition

PTC is proud to have been recognized for our strong culture and scientific innovation:

- Don Clifton Strength-Based Culture Award
- PTC Brazil certified as a *Great Place to Work*
- Recognized by EuropaBio as one of the top companies with a scientific breakthrough in last 25 years
- Evrysdi®(risdiplam) received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact
 - 2022 Drug Discovery of the Year award by British Pharmacological Society
 - 2021 Drug Discovery Prize by the Society for Medicines Research and Pharmaceutical Technology Sector Excellence award

PTC Expectations

How we operate as a #OnePTC company:



Our Environment





As a science-based company, we understand the impact people and companies have on the environment. We care about the world we live in and have a steadfast commitment to maintaining a healthy environment. We continuously ensure our actions are compliant with environmental requirements and regulations and encourage employee actions which are environmentally friendly.





- Our laboratories meet all environmental standards and have consistently passed inspections by multiple government authorities.
- We have installed charging stations for electric vehicles at our corporate headquarters.
- We have replaced lightbulbs in all buildings at our corporate headquarters with LED lighting.
- We have filtered water coolers in all facilities to encourage the use of tap water in lieu of using bottled water.
- We encourage our employees to use reusable water bottles, cups, plates, and silverware to reduce the use of paper or plastic.
- We have an active “Green Team” committee that takes action through recycling and reduction of food waste programs, as well as other environmental programs.
- Over 20% of electricity used at our South Plainfield research center is generated through wind power.
- We supported The Watershed Institute’s mission to protect and restore water and natural environment in central NJ through conservation, advocacy, science, and education.
- In 2021, PTC formed a Global Environmental Community Team with global representation to begin the journey of focusing on its corporate response to environmental sustainability and on individual employee behavioral changes at work and at home that supports sustainability.



Our Hopewell Community Volunteers at a Stream Clean-Up Event with The Watershed Institute in New Jersey

Organizers: JiaBei Zhang, Vanessa Bobeki, Laken Henry

"Thank you, Vanessa and JiaBei, for organizing this! It was a lot of fun and a great time bonding with the team."
—Bobby Stein

"It was a lot of fun! I'm glad to be a part of a company that focuses on the environment and know great people who care about it."
—Ryan Grant

"Your dedication as volunteers is an inspiration! Thank you for your energy, passion and hard work!"
—Vanessa Bobeki



Our Patients





Since our founding in 1998, PTC has concentrated on discovering, developing, and commercializing treatments for patients living with rare disorders leveraging our expertise in RNA biology. As we have grown, our technology platforms have expanded from this foundational scientific expertise to include multiple approaches including gene therapy.

Our Therapeutic Areas Encompass Genetic Disorders, Oncology, and Virology.

Genetic Disorders: Most genetic disorders are rare and affect one person in every several thousands. We are committed to discovering and developing therapeutics for patients living with genetic disorders with high unmet medical need and are currently focused in the areas of:

- AADC (aromatic L-amino acid decarboxylase) Deficiency
- Angelman Syndrome (AS)
- Duchenne Muscular Dystrophy (DMD)
- Familial Chylomicronemia Syndrome (FCS)
- Friedreich Ataxia (FA)
- Hereditary Transthyretin (hATTR) Amyloidosis
- Huntington's Disease (HD)
- Mitochondrial Disease Associated Seizures (MDAS)
- Phenylketonuria (PKU)
- Spinal Muscular Atrophy (SMA)

Oncology: PTC is developing innovative cancer treatments in:

- Acute Myeloid Leukemia (AML)
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Leiomyosarcoma (LMS)

Virology: PTC wanted to be part of the solution to help the world develop treatments to address the COVID-19 pandemic. We looked within our pipeline to determine whether we had potential therapies to treat COVID-19 patients. Emvododstat, a dihydroorotate dehydrogenase (DHODH) inhibitor, was shown to be a potential treatment. Emvododstat is in ongoing clinical trials.





Patient Advocacy

PTC's commitment to patient advocacy is a foundational hallmark of our company. Working with patients, families, those affected by rare disease, and non-profit organizations allows our patient relations team to better understand the patient experience and share those insights across PTC throughout the drug discovery and development process.

We have partnerships with more than 200 patient advocacy groups around the world to support patients with rare diseases. Today, we have multiple products on the market that are making a difference in the lives of patients and their families, and we have many more product candidates in our pipeline. We work with these advocacy groups to bring these therapies to patients.





Research & Development/Innovation

PTC has made significant investments to expand our research and development programs over the last year. Gene therapy holds tremendous promise for some of the most debilitating and intractable rare, genetic disorders. Last year, we commemorated the official opening of our 220,000-square-foot Center of Excellence for gene therapy manufacturing in Hopewell, New Jersey. The state-of-the-art biologics facility is perfectly equipped to handle process development (PD) and good manufacturing practice (GMP) of plasmids and adeno-associated virus (AAV) vectors, essential to PTC's robust rare disease gene therapy pipeline.

We are proud of our investment at the site, in addition to the significant growth we've made to our employee headcount, as part of our commitment to bring transformative new treatments to patients living with rare disease.





At PTC, patients fuel our commitment to develop therapies that provide transformative treatments. To celebrate the official opening of our new facility in Hopewell, NJ, PTC hosted a ribbon-cutting ceremony in October 2021.

During the Hopewell ribbon-cutting event, guest speaker Kyle Bryant, spokesperson for the Friedreich's Ataxia Research Alliance, delivered a moving speech on his rare disease journey and the hope for the future that gene therapy represents.



"In rare disease you know you feel so alone when you're first diagnosed and to have a facility like this dedicated to rare disease is really uplifting. I think it touches every single patient to know that this is for us! We are truly going to get to the finish line because of facilities just like this and amazing partners like PTC.

This facility will make drugs that do amazing things. But one of the most amazing things that it will make is hope for a better future for many people. That's a pretty powerful thing to manufacture."

—Kyle Bryant



By the Numbers

~300K sq ft of state-of-the-art research facilities to support and foster innovation

117% Expanded our fully operational footprint for research, development, and manufacturing facilities by 117% in 2021

65% 65%* cumulative investment in R&D

**As a percentage of Business Operation Expenses (GAAP R&D + SG&A)*





Building the Future of Manufacturing

To advance our internal gene therapy programs, the Center of Excellence includes laboratory space for plasmid DNA development, AAV process development, and analytical development. Additionally, it includes segregated GMP manufacturing suites for both plasmid DNA and AAV manufacturing as well as Quality Control Laboratories for raw material, in process and release testing for both drug substance and drug product.

PTC is planning to leverage its expertise and excess capacity to manufacture gene therapies for other biotechnology companies and research institutions.




Our Gene Therapy Center of Excellence includes laboratory space for plasmid DNA development, AAV process development, and analytical development. We are now seeking strategic partnerships with companies requiring plasmid DNA and AAV process development and/or GMP manufacturing.



Products & Pipeline

PTC has a robust pipeline filled with innovative compounds targeted at the underlying cause of diseases with high unmet medical need.



Clinical Trials

PTC has multiple registration-directed clinical trials that hold hope for many rare diseases. Many of these will read out in the near term.

Five Registration-Directed Clinical Trials Drives Near-Term Value





PTC Programs to Support Patient Communities and Access to Care

In 2021, we supported multiple organizations that assist patients with rare diseases and donated approximately \$2 million to these causes. Our current programs include:

- **STRIVE™:** Over the last seven years, PTC's STRIVE (Strategies to Realize Innovation, Vision and Empowerment) program has provided 35 grants to patient advocacy organizations in 20 countries to help realize meaningful projects that address the unmet needs of the rare disease community.

The STRIVE program global initiatives make a positive impact through increased awareness or diagnosis of Duchenne, advanced education, improved quality of life of patients, improved patient access to medical care or fostering of future patient advocates.

In 2021, we were proud to recognize three winning initiatives and communities who have continued to show uninterrupted resilience for the Duchenne community around the world:

- **Associação Gaúcha de Distrofia Muscular's (AGADIM) – Brazil:** With funding from the STRIVE Award, AGADIM will launch the project "Duchenne Community" to serve the evolving unmet needs of people with Duchenne. They aim to achieve this by creating a safe and empowering residential model and providing appropriate accommodation for adults living with Duchenne to call home, supported by specialist care. The

unique project will integrate those living with Duchenne into community life, providing tailored care services, support with decision making around daily activities, the possibility of a career and studying – to help them achieve their dreams for autonomy, where possible.

- **ASCADIM (Associação Sul Catarinense de Familiares, Amigos e Portadores de Distrofias Musculares Progressivas) – Brazil:** ASCADIM currently provides care to 22 patients, but with help from STRIVE funding, they plan to renovate their headquarters so that they can double the number of people they help, create a much-needed safe space and a sense of community, while still delivering a vital service. Improved facilities and equipment will allow this essential service to continue to support those living with Duchenne and expand to the broader muscular dystrophy community in Southern Brazil.
- **Pathfinders Neuromuscular Alliance – United Kingdom:** With the help of STRIVE Awards funding, Pathfinders will develop an inclusive suite of multi-media resources in partnership with young people living with Duchenne, providing information and advice for others on the same journey. They will address common key questions about transitioning into adulthood, along with sharing vital health messages and promoting the importance of neuromuscular specialists and their role in their care during this important life stage.





• **Insightful Moments™:** Insightful Moments is our community education series of programs and materials created to support patients with rare disease and their families. The programs empower patients and families through different learning styles and communication methods. The series covers a wide range of topics, from drug discovery and development to navigating clinical trials, insurance, government programs, holistic inspirations, and more.



• **PTC Pinpoint™:** We've partnered with Invitae to provide no-cost genetic testing, genetic counseling, and family screening programs for individuals with a suspected neurotransmitter disorder, such as AADC deficiency or cerebral palsy, in the U.S.



• **PTC Cares™:** Our support program in the U.S. dedicated to helping patients, caregivers, and prescribers understand the prescription process, financial assistance, and insurance information for PTC products.

SIBLING PROGRAM

• **Sibling Program:** Our established program allows certain siblings of our Duchenne clinical trial patients to have free access to our medicines.



• **Behind the Seizure®:** PTC is one of the sponsors for this innovative collaboration with Invitae, for a free genetic testing program for AADC deficiency.

Compassionate Care

PTC is committed to providing access to our treatments for patients around the world. We continue to work with patients from our clinical trials and medical experts to support families who live in regions of the world who are unable to obtain our products without PTC's direct support. We work with the various health agencies to increase access to our programs for all patients while we make our Compassionate Care program available.



Our People





Talent Planning

Careers With Purpose

We look at drug discovery and development in a completely different way. We use cutting-edge technologies and groundbreaking research techniques to develop therapies for patients living with serious and life-threatening conditions, such as rare genetic disorders and cancer. We combine our scientific expertise with a patient-centric treatment approach to create a new way of addressing rare disease. Everyone who works at PTC understands that the rare disease journey can be filled with ups and downs. Our work at PTC isn't just a job. It's a calling. And that philosophy is reflected in our #OnePTC culture.



By the Numbers



PTC now has more than 1,200 employees



Footprint in 50 countries



Workforce growth in 2021



Employee retention rate in 2021



20 offices worldwide



Employee advancement/promotion rate in 2021



Global Onboarding

PTC recognizes the importance of establishing appropriate new hire expectations on our culture, values, and behaviors when new colleagues join the company. The cross-functional Global Onboarding Committee’s mission is to ensure a quick and successful onboarding experience for all new hires. The team has established global standards, resources, surveys, and response teams when opportunities for improvement are identified. PTC also leverages an Onboarding Buddy program, which pairs new hires with an experienced colleague to help welcome and encourage them in their first three months by offering advice, guidance, and resources about PTC. In 2021, PTC onboarded approximately 400 employees and contractors globally. PTC consistently receives positive feedback on its successful programs as it continues to rapidly grow its workforce.

The global #OnePTC team is building a world of possibilities for rare disease patients and families.



Benefits & Wellbeing

Employee Benefits

PTC offers a wide variety of benefit options to meet the diverse needs of our employees. We are committed to ensuring that our benefits program offers meaningful choices plus valuable resources to support the moments that matter most. Our benefits evolve each year and are designed to ensure that our employees are healthy, and protected now and in the future. Our comprehensive benefits in the U.S. include:

- Medical, Dental & Vision Insurance
- Dependent and Health Flexible Spending Accounts and Health Savings Accounts
- Retirement Plan with Company Match
- Income Protection
- Employee Stock Purchase Plan
- Equity Awards
- Family Planning Benefits
- Tuition Reimbursement
- Remote Work/Schedule Flexibility
- Time-Off Programs
- Peer Recognition Program
- Global Wellbeing Program
- Caregiver Program for Children with Special Needs

Outside of the U.S., we also offer many of these benefits, as well as others consistent with local expectations for our industry in addition to applicable legal requirements.

Employee Relief Fund

PTC launched a global, non-profit charitable fund designed to help employees facing a financial hardship with a tax-free grant in their time of need, whether it is immediately after a natural disaster, during a pandemic, or due to an unforeseen personal hardship. While the Employee Relief Fund relies primarily on individual donations from employees, PTC made an initial contribution to seed the fund.

“Sept. 2 is a day that I will not soon forget; it was the day Hurricane Ida came and changed my life. Through this terrible time, I was so very thankful to find out PTC had taken immediate action to help those that had been affected. The process to apply for the grant was so simple and I received the funds soon after receiving an approval. I am forever grateful to my PTC family for being there for me and its employees in a time of great need, and in a time to rebuild what Ida had so quickly washed away.”

—Christina R., 2021 grant recipient for the PTC Employee Relief Fund





Learning & Development

PTC strives to support individuals, leaders, and teams to be the best they can be. We have created and implemented several top-of-the-line programs, tools, and processes to help our employees grow and be **ever better**.

Part of our key objectives is to build a strengths-based learning culture. As PTC continues to grow, we are committed to investing in leading-edge systems that will provide the very best experience for our employees. Access to a wide range of programs and platforms are available to all employees, including:

- **Gallup® CliftonStrengths & HBDI®:** We utilize the CliftonStrengths assessment and the Herrmann Brain Dominance Instrument (HBDI) assessment to identify each employee's top strengths and behavioral styles.
- **MindTools:** Our library of articles, modules, videos, and self-assessments focused on career skills, stress management, team management, and communication skills.
- **Learning Hub:** Our new Learning Management System (LMS) serves as the ultimate destination to explore learning and development content, as well as quality trainings.
- **PTC University:** Our company-wide education program features internal and external experts on a wide variety of topics, from business and science to sessions for personal enrichment.
- **Individual Strengths Coaching:** Our certified CliftonStrengths coaches offer one-on-one training sessions to every new hire in support of our coaching practices and Strengths-based culture.
- **Mentorship Roundtable by Directors of the Board:** This program currently provides an intimate forum for top talent to learn from our distinguished board, as well as a platform for the Board of Directors to become familiar with future leaders of PTC.



By the Numbers

CliftonStrengths & HBDI:

- 80+ Number of cumulative skills training sessions held
- 50+ Number of CS/HBDI sessions held

MindTools:

- 566 Total number of platform users in 2021
- 11k Total number of content views for mentorship and individual courses

Mentorship and Individual Strengths Coaching:

- 18 Certified internal strength coaches
- 80 Participants in the Mentoring Roundtable program



Enhancing Leadership Capabilities: We've also built a strong talent management program for leadership training throughout the organization. Our programs support employees with training and mentorships to be the next-generation company leaders. Our key initiatives included:

- **Emerging Leaders.** This new, six-month leadership development program was designed to inspire, challenge, and develop our global talent to be future leaders at PTC. Participants chosen for the program have the opportunity to interact with PTC's senior leaders, engage on relevant topics, and participate in a project to expand their business acumen. The first cohort kicked off the program in 2021, while plans for a second cohort are expected to continue in 2022.
- **Leadership Essentials.** In 2021, we conducted several training sessions for more than 200 leaders across the globe. This program focuses on introducing frameworks to elevate skills in communication, as well as both inclusive and situational leadership.
- **Boss to Coach.** We introduced Gallup's management development program to help managers further develop their leadership skills. The program provides participants with the principles, tools, and techniques to help managers learn how to be truly inspiring coaches.

Goals and Performance: At PTC, corporate goals and employee performance are managed through the system of OKRs, or "Objectives and Key Results," pioneered at Intel by Andy Grove and widely used in the technology industry. OKRs from the CEO on down are transparent to all employees through an internal system we developed and are refreshed and assessed on a quarterly basis.





Moment Makers

At PTC, we work hard to ensure our employees feel valued and are recognized for contributions professionally as well as personally. Our people at PTC often go above and beyond and have many stories, experiences, and moments that make a difference and impact the lives of our patients and colleagues. Their stories not only represent the great work being done at PTC, but they epitomize our values, passions, and expectations. PTC regularly highlights employee stories within the organization through a video series, *Moment Makers*.

Reuniting a Ukrainian Family: Moment Makers Exemplify PTC's 'Be Kind' Expectation in an Extraordinary Way

The inspiring story of how our global PTC employees came together to help a fellow colleague's family escape from harm's way when the conflict in Ukraine began is one of our most popular episodes to date. When Jesse Sibarium, based in Switzerland, and Ewa Gajak, based in Poland, learned that their New Jersey-based colleague Nadiya Sydorenko's sister and nephew were in danger in Ukraine, they each stepped up without hesitation to help reunite a family when it was needed most. Watch the video to hear their story.





Workplace & Employee Safety

PTC remains focused on providing employees with necessary safety measures and workplace flexibility.

Our Continued Response to COVID-19: PTC's COVID-19 Task Force continued to assess the pandemic and our response by monitoring global data and government guidelines, updating safety guidelines for our onsite and field-based employees, providing guidance on vaccines, and managing individual COVID-19 cases. The task force was able to achieve the following:

- Nearly **99%** of our global employees met government COVID-19 vaccine recommendations with **100%** of U.S. employees meeting our COVID-19 vaccine policy requirements
- Management of rules for working onsite, relaxing, and tightening standards based on geographical viral transmission rates and other local data



Our Culture & Community





We are dedicated and committed to enriching the PTC culture. We aspire to enhance the employee experience and empower our employees to make a difference within internal and external communities.

PTC's new, dedicated Culture & Community team is responsible for PTC's Equality, Diversity & Inclusion (ED&I) program, Global Onboarding, Global Employee Outreach, and PTC's response to COVID-19. By the end of 2021, more than 10% of PTC's global workforce served in at least one or more Culture & Community leadership roles delivering these global programs.

Global Equality, Diversity & Inclusion

Our ED&I program focuses on awareness, outreach and developing our talent pipeline. PTC recognizes that when employees understand and celebrate each other as whole persons, especially our differences, we are enabled to perform as teammates at the highest level.

In 2021, PTC completed the first year of its ED&I program guided by a steering committee comprised of senior leaders, volunteer ED&I ambassadors, and seven Employee Resource Groups (ERGs), including:

- 1 Asia Pacific Islander Alliance
- 2 Black Empowerment Council
- 3 Lesbian, Gay, Bi-sexual, Transgender and Queer/ Questioning and Allies
- 4 Multicultural Alliance Group of Inclusive Communities (Includes European, African and Middle East regions)
- 5 Organization for Latinx Allies
- 6 South America and Mexico Multicultural Alliance Plus
- 7 Women+ International Network


A Look at PTC's Employee Demographic Stats



Gender:
49.9% female
44.9% male
5.2% not declared/other



Organizational Levels:
40% of Board of Directors are female
45% of the Executive Committee is female



Ethnicity:
50.45% White
47.98% Non-White
1.57% Not Declared

**Based on data for employees in the U.S., due to individual geographic privacy and employment laws which prohibit collection of this information outside of the U.S.*



Approximately **200** employees worldwide participated in our newly launched ERGs by the close of 2021. ERGs meet monthly and spent the last year focused on **raising awareness of social and community issues** like women’s inequality, **responding to community needs** such as the rise in Asian-hate incidents, **responding to crisis** like those impacted by COVID-19 in Brazil, **celebrating important events** like Hispanic Heritage Month, and **providing community outreach** such as supporting underserved public-school students.

Global Employee Outreach

In 2021, PTC established a Global Outreach Steering Committee to focus on company-wide volunteer and giving opportunities.

The Global Outreach Grant Committee established the following guidelines:

- **Supporting STUDENTS** in public underserved schools near our corporate facilities to advance interest in STEM careers, including support for literacy development and mentoring
- **Supporting COMMUNITY NEEDS** near our facilities and/or in our regions for basic necessities
- **Supporting PATIENTS** (with rare diseases that PTC supports) with local activities and in coordination with our Patient Engagement team
- **Supporting PLANET/ENVIRONMENT** responsible activities with both corporate actions and individual activities that drive sustainability and transformation efforts which impact the world
- **Engaging in DISASTER RELIEF** efforts based on the impact to our mission to support patients or in response to requests by our employees





Global Outreach Efforts in 2021:

- Formed a Global Planet/Environmental Community Team to begin the journey of focusing on our corporate response to environmental sustainability and on individual employee behavioral changes at work and at home
- Donated to Students 2 Science to support virtual lab experiences to Passaic Academy of Science and Engineering (PASE)– a school PTC started a partnership with in 2017
- Prepared more than 110 school-supply packed backpacks for underserved students in partnership with Jersey Cares
- Provided matching grants to our employees' donations to disaster relief in India and Brazil during critical pandemic needs in these countries
- Supported the PARTAGER Project based in Brazil to become an official Non-Profit Organization, providing food and care for people in underserved communities. PTC raised funds and donated 250 food baskets for the organization
- Helped raise funds and donated to the Amigos do Bem nonprofit in Brazil, in support of needs for poor communities
- **Donated used and recycled laptops in Brazil and Colombia to support underprivileged students in need**



Colombian team donation for Fundación Sin Límite



The PTC team in Dublin, Ireland donated funds to help purchase essential supplies in partnership with the St. Andrews Board of Management to provide service to elderly and disadvantaged individuals in the local community during the COVID-19 crisis.





Talent Pipeline Program


Since 2020, the PTC Talent Pipeline Program (TPP) has provided recent graduates with a one-year global fellowship program to gain real-world experience in the biopharmaceutical industry and related professions, including research, finance, commercial, compliance, quality, legal, information technology, and communications.

TPP focuses on supporting recent students at the beginning of their careers with an immersive fellowship program that provides mentorship, job coaching, career counseling, and leadership training.

Fellow selection process, manager support and on-the-job activities are aligned with PTC's goal to attract, develop, and retain the best and brightest talent. PTC launched its latest application period in February 2022 and will select approximately 30 Fellows for a one-year program to begin in June.

TPP Alumni Spotlight

TPP alumni come from a variety of departments at PTC, including legal, regulatory, and pharmacology, reflecting the diversity of professions represented by this fellowship program. Here, a few of our alumni who are now full-time employees at PTC reflect on their experiences:



Kaleema Lewis

Research Associate II,
Pharmacology & Biomarkers (US)


"I am most proud that the research that I am doing as a part of the Pharmacology team may one day lead to a treatment or cure that could improve the quality of life for people with debilitating diseases."



Helena Feijo

Analyst Legal (Brazil)

"The visibility that PTC gives to all employees was a rewarding part of my experience. It's clear that PTC takes the "#OncePTC" mindset seriously."



Umbreen Majid

Staff Specialist Regulatory Affairs (US)

"The most rewarding part of my experience was seeing how open the company was to ideas and initiatives. My current full-time position here was created as a result of analyzing gaps in our current process and determining where our department needed resources."



The PTC Political Action Committee (PTC-PAC) is a key business tool for PTC. PTC-PAC allows PTC to build relationships with elected leaders and ensure that the voice of PTC employees and patients is heard on the issues that most deeply affect us. These include policies related to patient access to medicines, government reimbursement, the U.S. patent system, fostering an innovation-friendly business environment, the role of the federal government in research, and so much more. PTC-PAC brings the voice of PTC employees and patients to the forefront of public policy discussions.

Ethics & Compliance





Compliance Program

PTC conducts activities in accordance with applicable laws and regulations and is committed to acting honestly, ethically, and fairly. Our Global Compliance Program is a well-designed, effectively implemented program that includes written policies and procedures made available to all employees, a designated Chief Compliance Officer and Compliance Committee (including our heads of Quality and Regulatory) to oversee the program, routine training and education, as well as multiple channels to ask questions and raise concerns. PTC also routinely conducts internal monitoring and auditing of its business to help prevent and detect non-compliance with laws, regulations, or policy. Our Chief Compliance Officer has direct access to our CEO and to our Board for purposes of our Global Compliance Program without any requirement to consult with any members of management in advance.

Compliance App

A newly launched Compliance app is a one-stop-shop for Compliance information and helps consolidate and streamline important resources, including:

- Code of Business Conduct and Ethics
- Confidential Hotline
- Grants & Donations
- HCP/HCO Engagements

- Transparency & Reporting
- Third Party Due Diligence
- Privacy and Data Protection
- Country-specific Guidance


Code of Business Conduct and Ethics

PTC's Code of Business Conduct and Ethics sets the tone for our compliance standards and was developed as guidance to help us make the right ethical decisions while doing business on behalf of the company. The Code focuses on the expected standards of conduct as it relates to our **patients, employees, shareholders, business partners, and communities**.

The standards outlined in our Code apply to all officers, directors, and employees of PTC, as well as all our subsidiaries and affiliates worldwide. PTC expects its contractors, consultants and any other parties acting on behalf of the company to comply with all applicable laws and regulations, as well as with the compliance principles set forth in the Code. PTC remains committed to fostering an environment where open, honest communications are the expectation, not the exception. It is everyone's responsibility to do the right thing, support our culture, and conduct business with integrity, while feeling comfortable with approaching a supervisor or management in instances where they believe violations of policies or standards have occurred—without fear of retaliation.

Confidential Hotline

Our confidential hotline can be accessed 24 hours a day, 7 days a week and is offered in multiple languages. Concerns may be reported by phone or online. This hotline is monitored by a third-party and all reports to it are followed up in accordance with our policies.





Board of Directors

PTC's Board of Directors work with our management team to ensure that our culture is conducive to a productive and healthy work setting and that the Company approaches corporate governance, environmental and social issues in a way that is consistent with our culture.

	Audit Committee	Compensation Committee	Nominating and Corporate Governance Committee
Emma Reeve	👤		
Stephanie Okey			👤
Michael Schmertzler ★		👤	👤
Mary Smith		👤	
David P. Southwell	👤	👤	
Glenn D. Steele JR., MD, Ph.D		👤	
Dawn Svoronos	👤		👤
Jerome B. Zeldis, Ph.D.			👤

👤 = Chairperson 👤 = Member ★ = Chairman of the Board



Michael Schmertzler Chairman

Mr. Schmertzler has served as a member of PTC's Board of Directors since 2001 and as the Chairman of the Board since 2004.

He joined PTC's Board after leading the Series A investment in the company as Co-Head of Credit Suisse First Boston Equity Partners. Mr. Schmertzler is also currently a director of Berryville Holdings (a cybercommunications security software development company); Dispel (a secure remote access provider protecting critical infrastructure); and SHY Therapeutics (a small molecule therapeutics company). See full bio [here](#).



Allan Jacobson, Ph.D. University of Massachusetts Chan Medical School

Dr. Jacobson is a co-founder of PTC and is the Gerald L. and Zelda S. Haidak Distinguished Professor of Cell Biology at the University of Massachusetts Chan Medical School. He has served as a member of the PTC Board of Directors since the company's inception in 1998, previously served as Chairman of the Board of Directors from 1998 to 2004 and has served as Chairman of the Scientific Advisory Board since 2000. See full bio [here](#).



Stephanie S. Okey, M.S. Former SVP, Head of North America, Rare Disease – Genzyme

Ms. Okey has served as a member of PTC's Board of Directors since December 2018.

She has more than 30 years of experience in the biopharmaceutical industry, and most recently served as the Senior Vice President, Head of North America, Rare Diseases and U.S. General Manager, Rare Diseases at Genzyme, A Sanofi Company. Ms. Okey has significant experience in pre-launch, launch, and commercialization of rare and orphan disease products, as well as large market products. See full bio [here](#).



Stuart W. Peltz, Ph.D. CEO, PTC Therapeutics, Inc.

Dr. Peltz founded PTC in 1998 and has served as CEO and a member of the Board of Directors since the company's inception. Under his leadership, PTC has grown from a research organization to a publicly traded company on NASDAQ focused on the discovery, development, and commercialization of orally administered, small-molecule treatments for genetic disorders, oncology, and infectious diseases. Dr. Peltz is a recognized scientific leader in RNA biology for post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. See full bio [here](#).



Emma Reeve
Independent Board Director

Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies. Most recently, she served as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, prior to its acquisition by MorphoSys AG in 2021. Ms. Reeve led Constellation's initial public offering in 2018 and raised over \$700 million for the company during her tenure. See full bio [here](#).



Glenn D. Steele, Jr., M.D., Ph.D.
Chairman of GSteele Health Solutions

Dr. Steele serves as Chairman of GSteele Health Solutions, an independently operated venture launched to help healthcare organizations create value and improve quality. He is the former President and CEO of Geisinger Health System (2001-2015), an integrated health services organization nationally recognized for its innovative use of the electronic health record and the development and implementation of innovative care models. A prolific writer, he is the author or co-author of more than 500 scientific and professional articles. See full bio [here](#).



Mary L. Smith
The VENG Group

Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a \$6 billion division of the U.S. Department of Health & Human Services and system of hospitals providing healthcare to more than 2 million Native Americans in the U.S. She currently serves as Vice-Chair at the VENG Group where she consults clients on business development, strategy, healthcare, and corporate governance. Additionally, Ms. Smith founded the Caroline and Ora Smith Foundation, which sponsors, supports, and trains Native American girls in science, technology, engineering, and math. See full bio [here](#).



Dawn Svoronos
**Former President of Merck's Europe/
Canada Region**

Ms. Svoronos has served as a member of PTC's Board of Directors since June 2016. She has more than 30 years of experience in the pharmaceutical industry, including extensive commercial work at Merck & Co. Inc., where she held roles of increasing seniority for 23 years. Ms. Svoronos is currently Chair of the Board of Directors for Theratechnologies Inc., a specialty pharmaceutical company that trades on the Toronto Stock Exchange as well as the NASDAQ Exchange. See full bio [here](#).



David P. Southwell
CEO, TScan Therapeutics

Mr. Southwell has served as a member of PTC's Board of Directors since December 2005. He is currently the CEO of TScan Therapeutics, an oncology-focused cell therapy biotechnology company. He served as President and CEO and member of the Board of Directors of Inotek Pharmaceuticals from August 2014 until its merger with Rocket Pharmaceuticals in January 2018. He also serves on the Board of Directors of Rocket Pharmaceuticals and TScan Therapeutics, Inc. See full bio [here](#).



Jerome B. Zeldis, M.D., Ph.D.
NexImmune, Inc.

Dr. Zeldis has served as a member of PTC's Board of Directors since September 2012. He is currently the Executive Vice President of NexImmune Corporation. Until June 2016, Dr. Zeldis served as Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he was employed since 1997. Dr. Zeldis also serves on the Board of Directors of Soligenix and BioSig Technologies. See full bio [here](#).



Privacy Policies & Cybersecurity

The objective of PTC's cybersecurity program together with the data protection and privacy program is to ensure the protection of all sensitive data which includes, but is not limited to, patient personal data, healthcare professionals' personal information, employment and human resource data, web visitors' data, personally identifiable information (PII), clinical trial data, operational data, financial data, and intellectual property. PTC takes steps to protect this data from loss, misuse, and unauthorized access, disclosure, alteration, or destruction. We respect personal privacy and apply appropriate data protection measures to respect these rights. Any concerns related to a potential or actual breach of personal information are considered serious in nature and are thoroughly investigated. Our Chief Information Officer sits on our Compliance Committee, which oversees the outcome of cybersecurity investigations, and direct access to our CEO and Board for this purpose without any requirement to consult with management in advance.

PTC accomplishes this by following cybersecurity industry best practices as outlined in The National Institute of Standards and Technology (NIST) through the implementation of technical, administrative, and operational controls. These controls create multiple defensive layers to protect sensitive data by ensuring confidentiality, integrity, availability, and resilience of processing systems and services.

Everyone in the company has a role to play in protecting and securing personal information. PTC is committed to the lawful stewardship of personal information that is collected, stored, and used by the Company.

This is achieved through multiple learning opportunities with topics that include, but are not limited to email, internet browsing, and sensitive data handling.

PTC maintains an enterprise-wide policy and standards that guide the collection, use, maintenance, and protection of personal data and consider the legal and regulatory requirements in countries where we do business. These standards include, but are not limited to:

- Anonymization
- Asset Management
- Authentication
- Encryption
- Identity Management
- Access Control
- Physical Access
- Pseudonymization
- Third-Party Risk Mitigation

